| 张 燕,廖大忠,刘成凤,赵曼妤,严佳佳.宫颈癌患者新辅助化疗前后miR-138的表达及与化疗敏感性的关系研究[J].现代生物医学进展英文版,2019,19(9):1782-1785. |
| 宫颈癌患者新辅助化疗前后miR-138的表达及与化疗敏感性的关系研究 |
| Expression of microRNA-138 in Cervical Cancer Patients Before and after Neoadjuvant Chemotherapy and its Relationship with Chemotherapy Sensitivity |
| Received:January 10, 2019 Revised:January 31, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.09.040 |
| 中文关键词: 宫颈癌 新辅助化疗 miR-138 敏感性 |
| 英文关键词: Cervical cancer Neoadjuvant chemotherapy miR-138 Sensitivity |
| 基金项目:四川省卫生和计划生育委员会科研项目（15PJ3151） |
| Author Name | Affiliation | E-mail | | ZHANG Yan | Department of Oncology and Hematology, Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University, Luzhou, Sichuan, 646000, China | 113804562@qq.com | | LIAO Da-zhong | Department of Oncology and Hematology, Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University, Luzhou, Sichuan, 646000, China | | | LIU Cheng-feng | Department of Oncology and Hematology, Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University, Luzhou, Sichuan, 646000, China | | | ZHAO Man-yu | Department of Oncology and Hematology, Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University, Luzhou, Sichuan, 646000, China | | | YAN Jia-jia | College of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, Sichuan, 646000, China | |
|
| Hits: 779 |
| Download times: 630 |
| 中文摘要: |
| 摘要 目的：研究宫颈癌患者新辅助化疗前后微小RNA-138（miR-138）的表达及与化疗敏感性的关系。方法：选取2016年2月至2018年7月我院收治的宫颈癌患者18例为研究对象。所有患者均给予新辅助化疗，并根据治疗后的效果分为化疗有效组与化疗无效组。采用微阵列芯片技术分别检测两组患者化疗前后的miR-138表达水平，同时采用Western blot技术检测miR-138基因靶蛋白γH2AX的表达情况，分析患者化疗后miR-138表达水平与临床病理特征的关系。结果：化疗有效组化疗后miR-138△Ct值明显低于化疗前，且明显低于化疗无效组（P＜0.05），而化疗无效组化疗后miR-138△Ct值与化疗前比较差异无统计学意义（P＞0.05）。化疗后两组靶蛋白γH2AX相对表达量均明显低于化疗前（P＜0.05），化疗有效组靶蛋白γH2AX相对表达量的差值显著低于化疗无效组（P＜0.05）。宫颈癌患者新辅助化疗后组织中miR-138△Ct差值与肿瘤分化程度、浸润深度和淋巴结转移密切相关（P＜0.05），与年龄、FIGO临床分期无关（P>0.05）。结论：新辅助化疗可以改变宫颈癌患者的miR-138表达水平，且miR-138的表达水平可能与化疗药物敏感性密切相关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the expression of microRNA-138(miR-138) in cervical cancer patients before and after neoadju- vant chemotherapy and its relationship with chemotherapy sensitivity. Methods: 18 patients with cervical cancer admitted to our hospital from February 2016 to July 2018 were selected as the study subjects. All patients were given neoadjuvant chemotherapy, and were divid- ed into chemotherapy effective group and chemotherapy ineffective group according to the effect of treatment. Microarray technology was used to detect the expression of miR-138 in two groups before and after chemotherapy. Western blot was used to detect the expres- sion of target protein γH2AX of miR-138 gene. The relationship between the expression level of miR-138 and clinicopathological char- acteristics was analyzed. Results: The miR-138△Ct value after chemotherapy in chemotherapy effective group was significantly lower than that before chemotherapy, and significantly lower than that chemotherapy ineffective group (P<0.05). However, there was no signifi- cant difference in miR-138△Ct value between after chemotherapy and before chemotherapy in chemotherapy ineffective group (P>0.05). The relative expression of target protein γH2AX after chemotherapy in the two groups was significantly lower than that before chemotherapy (P<0.05), and the difference of relative expression of target protein γH2AX in chemotherapy effective group was signifi- cantly lower than that in chemotherapy ineffective group (P<0.05). The miR-138△Ct difference value in cervical cancer tissues after neoadjuvant chemotherapy was closely related to the degree of differentiation, depth of invasion and lymph node metastasis (P<0.05), but not related to age and FIGO clinical stage (P>0.05). Conclusion: Neoadjuvant chemotherapy can change the expression of miR-138 in pa- tients with cervical cancer, and the expression of miR-138 may be closely related to chemosensitivity. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
